Progesterone antagonists and progesterone receptor modulators

Expert Opinion on Investigational Drugs

Volumn 12, Issue 10, 2003, Pages 1693-1707

  Spitz, Irving M ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b POPULATION COUNCIL   (United States)

Author keywords

Contraception; Emergency contraception; Endometrial effects; Endometriosis; GeneSwitch; Mechanism of action; Mifepristone; Myoma; PAs; PR; PR subunits; PRMs; SPRMs

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; ALKALINE PHOSPHATASE; ANTIGESTAGEN; AROMATASE INHIBITOR; ASOPRISNIL; CORTICOTROPIN; DANAZOL; ERYTHROPOIETIN; ESTRADIOL; ESTRONE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETOPOSIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; HORMONE ANTAGONIST; HORMONE RECEPTOR AFFECTING AGENT; HYDROCORTISONE; J 1042; J 956; LEVONORGESTREL; LUTEINIZING HORMONE; MIFEPRISTONE; ONAPRISTONE; ORAL CONTRACEPTIVE AGENT; POSTCOITUS CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; SYNAPTOTAGMIN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 137316;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANIMAL; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRACEPTION; DRUG ADMINISTRATION; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; EDEMA; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; FEMALE; GENE EXPRESSION REGULATION; GENE SWITCHING; GENE TRANSFER; HEADACHE; HORMONE INHIBITION; HUMAN; LEIOMYOMA; LUTEINIZING HORMONE RELEASE; MASTALGIA; METABOLISM; NAUSEA AND VOMITING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOPOROSIS; OVARY FOLLICLE DEVELOPMENT; PLASMID; PREGNANCY TERMINATION; RAT; REVIEW; UTERUS CANCER; UTERUS MYOMA; VAGINA BLEEDING;

ANIMALS; CONTRACEPTIVES, POSTCOITAL; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; GENE TRANSFER TECHNIQUES; HORMONE ANTAGONISTS; HUMANS; LEIOMYOMA; MIFEPRISTONE; PROGESTERONE; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

EID: 0142210295     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.10.1693     Document Type: Review

References (106)

1. PHILIBERT D, DERAEDT R, TEUTSCH G: RU 38486: a potent antiglucocorticoid in vivo. VII International Congress of Pharmacology, Tokyo, Japan (1981).
2. SPITZ IM, CROXATTO HB, ROBBINS A: Antiprogestins: mechanism of action and contraceptive potential. Ann. Rev. Pharmacol. Toxicol. (1996) 36:47-81.
3. LEONHARDT SA, EDWARDS DP: Mechanism of action of progesterone antagonists. Exp. Biol. Med. (Maywood) (2002) 227:969-980.
4. GIANGRANDE PH, MCDONNELL DP: The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog. Horm. Res. (1999) 54:291-313; discussion 313-314.
5. KASTNER P, KRUST A, TURCOTTE B et al.: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. (1990) 9:1603-1614.
6. WAGNER BL, NORRIS JD, KNOTTS TA, WEIGEL NL, MCDONNELL DP: The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromocyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol. Cell. Biol. (1998) 18:1369-1378.
7. LIU Z, AUBOEUF D, WONG J et al.: Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. USA (2002) 99:7940-7944.
8. SPITZ IM, CHWALISZ K: Progesterone receptor modulators and progesterone antagonists in women's health. Steroids (2000) 65:807-815.
9. SPITZ IM: Preface. Steroids (2000) 65:543-544.
10. ELGER W, BARTLEY J, SCHNEIDER B, KAUFMANN G, SCHUBERT G, CHWALISZ K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids (2000) 65:713-723.
11. KLEIN HITPASS L, CATO AC, HENDERSON D, RYFFEL GU: Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. (1991) 19:1227-1234.
12. GASS EK, LEONHARDT SA, NORDEEN SK, EDWARDS DP: The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology (1998) 139:1905-1919.
13. ONATE SA, TSAI SY, TSAI MJ, O'MALLEY BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (1995) 270:1354-1357.
14. VEGETO E, ALLAN GF, SCHRADER WT, TSAI MJ, MCDONNELL DP, O'MALLEY BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell (1992) 69:703-713.
15. BENHAMOU B, GARCIA T, LEROUGE T et al.: A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science (1992) 255:206-209.
16. TUNG L, MOHAMED MK, HOEFFLER JP, TAKIMOTO GS, HORWITZ KB: Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol. Endocrinol. (1993) 7:1256-1265.
17. VEGETO E, SHAHBAZ MM, WEN DX, GOLDMAN ME, O'MALLEY BW, MCDONNELL DP: Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol. (1993) 7:1244-1255.
18. MCDONNELL DP, SHAHBAZ MM, VEGETO E, GOLDMAN ME: The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J. Steroid Biochem. Mol. Biol. (1994) 48:425-432.
19. MCDONNELL DP, GOLDMAN ME: RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J. Biol. Chem. (1994) 269:11945-11949.
20. MCPHAIL MK. J. Physiol. (1934) 83:145-156.
21. PHILIBERT D: RU38486: An original multifaceted antihormone in vivo. In: Adrenal Steroid Antagonism. M Agarwal (Ed.), Walter de Gruyter and Co., Berlin (1984):77-101.
22. FUHRMANN U, HESS STUMPP H, CLEVE A et al.: Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J. Med. Chem. (2000) 43:5010-5016.
23. SARTORIUS CA, TUNG L, TAKIMOTO GS, HORWITZ KB: Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J. Biol. Chem. (1993) 268:9262-9266.
24. BECK CA, WEIGEL NL, MOYER ML, NORDEEN SK, EDWARDS DP: The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. USA (1993) 90:4441-4445.
25. WAGNER BL, POLLIO G, LEONHARDT S et al.: 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc. Natl. Acad. Sci. USA (1996) 93:8739-8744.
26. GLASIER A, THONG KJ, DEWAR M, MACKIE M, BAIRD DT: Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N. Engl. J. Med. (1992) 327:1041-1044.
27. WEBB AM, RUSSELL J, ELSTEIN M: Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. Br. Med. J. (1992) 305:927-931.
28. ASHOK PW, STALDER C, WAGAARACHCHI PT, FLETT GM, MELVIN L, TEMPLETON A: A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. Br. J. Obstet. Gynaecol. (2002) 109:553-560.
29. VON HERTZEN H, PIAGGIO G, DING J et al.: Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet (2002) 360:1803-1810.
30. ASHOK PW, WAGAARACHCHI PT, FLETT GM, TEMPLETON A: Mifepristone as a late post-coital contraceptive. Hum. Reprod. (2001) 16:72-75.
31. WORLD HEALTH ORGANIZATION TASK FORCE ON POSTOVULATORY METHODS OF FERTILITY REGULATION: Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet (1999) 353:697-702.
32. XIAO BL, VON HERTZEN H, ZHAO H, PIAGGIO G: A randomized double-blind comparison of two single doses of mifepristone for emergency contraception. Hum. Reprod. (2002) 17:3084-3089.
33. TRUSSELL J, RODRIGUEZ G, ELLERTSON C: New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception (1998) 57:363-369.
34. WILCOX AJ, WEINBERG CR, BAIRD DD: Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N. Engl. J. Med. (1995) 333:1517-1521.
35. GRAVANIS A, SCHAISON G, GEORGE M et al.: Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J. Clin. Endocrinol. Metab. (1985) 60:156-163.
36. HODGEN GD, VAN UEM JF, CHILLIK CF et al.: Non-competitive antioestrogenic activity of progesterone antagonists in primate models. Hum. Reprod. (1994) 9(Suppl. 1):77-81.
37. SLAYDEN OD, ZELINSKI-WOOTEN MB, CHWALISZ K, STOUFFER RL, BRENNER RM: Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum. Reprod. (1998) 13:269-277.
38. SLAYDEN OD, BRENNER RM: RU 486 action after estrogen priming in the endometrium, and oviducts of rhesus monkeys (Macaca mulatta). J. Clin. Endocrinol. Metab. (1994) 78:440-448.
39. BAIRD DT, BROWN A, CRITCHLEY HO, WILLIAMS AR, LIN S, CHENG L: Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. (2003) 18:61-68.
40. GROW DR, WILLIAMS RF, HSIU JG, HODGEN GD: Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J. Clin. Endocrinol. Metab. (1996) 81:1933-1939.
41. ZELINSKI-WOOTEN MB, SLAYDEN OD, CHWALISZ K, HESS DL, BRENNER RM, STOUFFER RL: Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity. Hum. Reprod. (1998) 13:259-267.
42. CHWALISZ K, BRENNER RM, FUHRMANN UU, HESS STUMPP H, ELGER W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids (2000) 65:741-751.
43. KOJI T, CHEDID M, RUBIN JS et al.: Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. J. Cell Biol. (1994) 125:393-401.
44. GROW DR, REECE MT, HSIU JG et al.: Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Fertil. Steril. (1998) 69:936-943.
45. GREB RR, HEIKINHEIMO O, WILLIAMS RF, HODGEN GD, GOODMAN AL: Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum. Reprod. (1997) 12:1280-1292.
46. HEIKINHEIMO O, HSIU JG, GORDON K et al.: Endometrial effects of RU486 in primates-antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J. Steroid Biochem. Mol. Biol. (1996) 59:179-190.
47. PARTHASARATHY S, MORALES AJ, MURPHY AA: Antioxidant: a new role for RU-486 and related compounds. J. Clin. Invest. (1994) 94:1990-1995.
48. NEULEN J, WILLIAMS RF, BRECKWOLDT M, CHWALISZ K, BAULIEU EE, HODGEN GD: Noncompetitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Hum. Reprod. (1996) 11:1533-1537.
49. BRENNER RM, SLAYDEN OD, CRITCHLEY HO: Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction (2002) 124:167-172.
50. SLAYDEN OD, BRENNER RM: Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J. Clin. Endocrinol. Metab. (2003) 88:946-949.
51. CHWALISZ K, STOCKEMANN K, FRITZEMEIER KH, FUHRMANN U: Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update (1998) 4:570-583.
52. RUMPEL E, MICHNA H, KUHNEL W: Morphology of the rat uterus after long-term treatment with progesterone antagonists. Anat. Anz. (1993) 175:141-149.
53. BIGSBY RM, YOUNG PC: Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus. Am. J. Obstet. Gynecol. (1994) 171:188-194.
54. NEWFIELD RS, SPITZ IM, ISACSON C, NEW MI: Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. (Oxf.) (2001) 54:399-404.
55. GRUNBERG SM: Role of antiprogestational therapy for meningiomas. Hum. Reprod. (1994) 9(Suppl. 1):202-207.
56. GRUNBERG SM, RANKIN C, TOWNSEND J et al.: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. American Society of Clinical Oncology, San Francisco, CA, USA (2001) 20.
57. GRUNBERG SM, WEISS MH, SPITZ IM et al.: Treatment of unresecatable meningiomas with the antiprogesterone agent mifepristone. J. Neurosurg. (1991) 74:861-864.
58. MARTINEAU PA, LEVENTAL M: Large endometrial polyp in a patient on long-term mifepristone therapy. J. Ultrasound Med. (2000) 19:487-489.
59. FLEISCHER AC, WHEELER JE, YEH IT, KRAVITZ B, JENSEN C, MACDONALD B: Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J. Ultrasound Med. (1999) 18:503-512.
60. LIEDMAN R, LINDAHL B, ANDOLF E, WILLEN R, INGVAR C, RANSTAM J: Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. (2000) 20:4889-4891.
61. MURPHY AA, CASTELLANO PZ: RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr. Opin. Obstet. Gynecol. (1994) 6:269-278.
62. MURPHY AA, KETTEL LM, MORALES AJ, ROBERTS V, PARMLEY T, YEN SS: Endometrial effects of long-term low-dose administration of RU486. Fertil. Steril. (1995) 63:761-766.
63. EISINGER SH, MELDRUM S, FISCELLA K, LE ROUX HD, GUZICK DS: Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. (2003) 101:243-250.
64. CROXATTO HB, KOVACS L, MASSAI R et al.: Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. (1998) 13:793-798.
65. LAMBERTS SW, KOPER JW, DE JONG FH: The endocrine effects of long-term treatment with mifepristone (RU 486). J. Clin. Endocrinol. Metab. (1991) 73:187-191.
66. HEIKINHEIMO O, RANTA S, GRUNBERG S, LAHTEENMAKI P, SPITZ IM: Alterations in the pituitary-thyroid and pituitary-adrenal axes-consequences of long-term mifepristone treatment. Metabolism (1997) 46:292-296.
67. HEIKINHEIMO O, RANTA S, GRUNBERG S, SPITZ IM: Alterations in sex steroids and gonadotropins in postmenopausal women subsequent to long-term mifepristone administration. Steroids (2000) 65:831-836.
68. SCHMIDT M, LOFFLER G: RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells. J. Steroid Biochem. Mol. Biol. (1997) 60:197-204.
69. TSENG L, MAZELLA J, SUN B: Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486. Endocrinology (1986) 118:1312-1318.
70. CROXATTO HB, SALVATIERRA AM, CROXATTO HD, FUENTEALBA B: Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod. (1993) 8:201-207.
71. WEIHUA Z, SAJI S, MAKINEN S et al.: Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Natl. Acad. Sci. USA (2000) 97:5936-5941.
72. HALL JM, MCDONNELL DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 140:5566-5578.
73. ZOU A, MARSCHKE KB, ARNOLD KE et al.: Estrogen, receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol. (1999) 13:418-430.
74. MULAC JERICEVIC B, MULLINAX RA, DEMAYO FJ, LYDON JP, CONNEELY OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 289:1751-1754.
75. ENGLUND K, BLANCK A, GUSTAVSSON I et al.: Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J. Clin. Endocrinol. Metab. (1998) 83:4092-4096.
76. BRANDON DD, BETHEA CL, STRAWN EY et al.: Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am. J. Obstet. Gynecol. (1993) 169:78-85.
77. YEN SSC: Use of antiprogestins in the management of endometriosis and leiomyoma. MS Donaldson, L Dorflinger, SS Brown, LZ Benet (Eds). In: Clinical Applications of Mifepristone (RU496) and other Antiprogestins. National Academy Press, Washington DC (1993):189-209.
78. YANG Y, ZHENG S, LI K: Treatment of Uterine Leimyoma by two different doses of mifepristone. Chin. J. Obstet. Gynecol. (1996) 31:624-626.
79. ZENG C, GU M, HUANG H: [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]. Zhonghua Fu Chan Ke Za Zhi (1998) 33:490-492.
80. CHWALISZ K, PARKER L, WILLIAMSON S: Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM). J. Soc. Gynecol. Investig. (2003) 10:301A
81. KETTEL LM, MURPHY AA, MORALES AJ, RIVIER J, VALE W, YEN SS: Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil. Steril. (1993) 60:642-646.
82. KETTEL LM, MURPHY AA, MORALES AJ, ULMANN A, BAULIEU EE, YEN SS: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. (1996) 65:23-28.
83. KETTEL LM, MURPHY AA, MORALES AJ, YEN SS: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am. J. Obstet. Gynecol. (1998) 178:1151-1156.
84. HAN S, SIDELL N: RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J. Clin. Endocrinol. Metab. (2003) 88:713-719.
85. BYGDEMAN M, DANIELSSON KG, MARIONS L, SWAHN ML: Contraceptive use of antiprogestin. Eur. J. Contracept. Reprod. Health Care (1999) 4:103-107.
86. SPITZ IM, VAN LOOK PF, COELINGH BENNINK HJ: The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids (2000) 65:817-823.
87. CAMERON ST, CRITCHLEY HO, THONG KJ, BUCKLEY CH, WILLIAMS AR, BAIRD DT: Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum. Reprod. (1996) 11:2518-2526.
88. BROWN A, CHENG L, LIN S, BAIRD DT: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J. Clin. Endocrinol. Metab. (2002) 87:63-70.
89. SARKAR NN: The potential of mifepristone (RU486) as a female contraceptive drug. Int. J. Clin. Pract. (2002) 56:140-144.
90. BORMAN SM, SCHWINOF KM, NIEMEYER C, CHWALISZ K, STOUFFER RL, ZELINSKI WOOTEN MB: Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment. Hum. Reprod. (2003) 18:69-76.
91. MARIONS L, DANIELSSON KG, SWAHN ML, BYGDEMAN M: Contraceptive efficacy of low doses of mifepristone. Fertil. Steril. (1998) 70:813-816.
92. MARIONS L, VISKI S, GEMZELL-DANIELSSON K et al.: Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum. Reprod. (1999) 14:2788-2790.
93. GEMZELL DANIELSSON K, SWAHN ML, SVALANDER P, BYGDEMAN M: Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum. Reprod. (1993) 8:870-873.
94. HAPANGAMA DK, BROWN A, GLASIER AF, BAIRD DT: Feasibility of administering mifepristone as a once a month contraceptive pill. Hum. Reprod. (2001) 16:1145-1150.
95. WORLD HEALTH ORGANIZATION TASK FORCE ON POST-OVULATORY METHODS OF FERTILITY REGULATION: Menstrual regulation by mifepristone plus prostaglandin: results from a multicenrte trial. Hum. Reprod. (1995) 10:308-314.
96. SWAHN ML, BYGDEMAN M, CHEN JK et al: Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol. Hum. Reprod. (1999) 14:485-488.
97. GEMZELL DANIELSSON K, VAN HEUSDEN AM, KILLICK SR et al.: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum. Reprod. (2002) 17:2588-2593.
98. WANG Y, O'MALLEY BW Jr, TSAI SY, O'MALLEY BW: A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA (1994) 91:8180-8184.
99. BURCIN MM, SCHIEDNER G, KOCHANEK S, TSAI SY, O'MALLEY BW: Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA (1999) 96:355-360.
100. SMITH LC, NORDSTROM JL: Advances in plasmid gene delivery and expression in skeletal muscle. Curr. Opin. Mol. Ther. (2000) 2:150-154.
101. ABRUZZESE RV, GODIN D, MEHTA V et al.: Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol. Ther. (2000) 2:276-287.
102. NORDSTROM JL: The antiprogestin-dependent GeneSwitch® system for regulated gene therapy. Steroids (In press).
103. MANGAL RK, WIEHLE RD, POINDEXTER AN 3rd, WEIGEL NL: Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J. Steroid. Biochem. Mol. Biol. (1997) 63:195-202.
104. ARNETT MANSFIELD RL, DEFAZIO A, WAIN GV et al.: Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. (2001) 61:4576-4582.
105. FRIEDMAN AJ, BARBIERI RL, DOUBILET PM, FINE C, SCHIFF I: A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil. Steril. (1988) 49:404-409.
106. SPITZ IM: Progesterone antagonists and progesterone receptor modulators: an overview. Steroids (2003) (In press).